---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-094535"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2023-12-11T23:59:59+00:00"
generated_at: "2026-06-07T15:08:35.520977+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics terminates CEO James Cullem, appoints Thomas Jensen as CEO

## Summary
- James Cullem terminated as CEO and all other positions on December 8, 2023.
- Thomas Jensen appointed CEO effective December 8, 2023; previously SVP of Investor Relations and IT.
- Jensen co-founded Allarity Therapeutics A/S in 2004 and leads the Denmark laboratories.
- Audit committee entered consulting agreement with Dr. Jeremy R. Graff for R&D advisory on small molecule inhibitors.
- No material plan or arrangement yet in place for new CEO's compensation.

## SEC filing metadata
- accession: 0001213900-23-094535
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2023-12-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390023094535/0001213900-23-094535-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390023094535/ea189774-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-094535
- JSON: https://secwatch.observer/filing/0001213900-23-094535.json
- Plain text: https://secwatch.observer/filing/0001213900-23-094535.txt

## Key facts
- Executive change
  James Cullem was terminated as Chief Executive Officer at Allarity Therapeutics, Inc..
  - Action: terminated
  - Role: Chief Executive Officer
  source text: On December 8, 2023, Mr. James Cullem was terminated as Chief Executive Officer of Allarity Therapeutics, Inc. (the “Company”) and all other positions with the Company and its subsidiaries.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023094535/0001213900-23-094535-index.htm
- Executive change
  Thomas Jensen was appointed as Chief Executive Officer at Allarity Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On December 8, 2023, Mr. Thomas Jensen, age 45, was appointed by the Company’s Board of Directors as Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023094535/0001213900-23-094535-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.